These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24940556)

  • 1. Topical Naltrexone as Treatment for Type 2 Diabetic Cutaneous Wounds.
    Immonen JA; Zagon IS; McLaughlin PJ
    Adv Wound Care (New Rochelle); 2014 Jun; 3(6):419-427. PubMed ID: 24940556
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
    Immonen JA; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats.
    Immonen JA; Zagon IS; Lewis GS; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 Oct; 238(10):1127-35. PubMed ID: 23986225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical Naltrexone Is a Safe and Effective Alternative to Standard Treatment of Diabetic Wounds.
    McLaughlin PJ; Cain JD; Titunick MB; Sassani JW; Zagon IS
    Adv Wound Care (New Rochelle); 2017 Sep; 6(9):279-288. PubMed ID: 28894635
    [No Abstract]   [Full Text] [Related]  

  • 5. Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats.
    McLaughlin PJ; Pothering CA; Immonen JA; Zagon IS
    Exp Biol Med (Maywood); 2011 Oct; 236(10):1122-32. PubMed ID: 21917593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical naltrexone accelerates full-thickness wound closure in type 1 diabetic rats by stimulating angiogenesis.
    McLaughlin PJ; Immonen JA; Zagon IS
    Exp Biol Med (Maywood); 2013 Jul; 238(7):733-43. PubMed ID: 23788174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.
    McLaughlin PJ; Sassani JW; Klocek MS; Zagon IS
    Brain Res Bull; 2010 Feb; 81(2-3):236-47. PubMed ID: 19683562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of the OGF-OGFr pathway in diabetic bone.
    Titunick MB; Lewis GS; Cain JD; Zagon IS; McLaughlin PJ
    Connect Tissue Res; 2019 Nov; 60(6):521-529. PubMed ID: 30931654
    [No Abstract]   [Full Text] [Related]  

  • 9. Topical naltrexone increases aquaporin 5 production in the lacrimal gland and restores tear production in diabetic rats.
    Diaz D; Sassani JP; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2024; 249():10175. PubMed ID: 38756167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone.
    Zagon IS; Sassani JW; Immonen JA; McLaughlin PJ
    Clin Exp Ophthalmol; 2014 Mar; 42(2):159-68. PubMed ID: 23777539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular surface complications result from dysregulation of the OGF-OGFr signaling pathway in female diabetic rats.
    Purushothaman I; Zagon IS; Sassani JW; Mclaughlin PJ
    Exp Ther Med; 2021 Jul; 22(1):687. PubMed ID: 33986852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats.
    Klocek MS; Sassani JW; McLaughlin PJ; Zagon IS
    Exp Eye Res; 2009 Nov; 89(5):686-92. PubMed ID: 19576213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reepithelialization of the human cornea is regulated by endogenous opioids.
    Zagon IS; Sassani JW; McLaughlin PJ
    Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):73-81. PubMed ID: 10634604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topically applied naltrexone restores corneal reepithelialization in diabetic rats.
    Klocek MS; Sassani JW; McLaughlin PJ; Zagon IS
    J Ocul Pharmacol Ther; 2007 Apr; 23(2):89-102. PubMed ID: 17444796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.
    Zagon IS; Sassani JW; Purushothaman I; McLaughlin PJ
    Exp Biol Med (Maywood); 2021 Mar; 246(5):629-636. PubMed ID: 33203224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits.
    Zagon IS; Sassani JW; Carroll MA; McLaughlin PJ
    Brain Res Bull; 2010 Feb; 81(2-3):248-55. PubMed ID: 19853024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Yin and Yang of the Opioid Growth Regulatory System: Focus on Diabetes-The Lorenz E. Zimmerman Tribute Lecture.
    Sassani JW; Mc Laughlin PJ; Zagon IS
    J Diabetes Res; 2016; 2016():9703729. PubMed ID: 27703986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats.
    McLaughlin PJ; Sassani JW; Diaz D; Zagon IS
    J Diabetes Clin Res; 2023; 5(1):1-10. PubMed ID: 37304310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
    McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
    BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Ludwig MD; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.